In today's episode, we welcome Dr. Sandip Patel, who is a Professor of Medical Oncology at the University of California, San Diego, to discuss the evolution of molecular profiling technology, focusing on how next-generation sequencing can help support patients with advanced thyroid cancer, but also how to integrate molecular profiling into clinical practice. Learning Objective(s): After completing this educational activity, learners will be able to discuss precision medicine and new technologies, including liquid biopsy Funding Information: This independent educational activity is supported b ..read more

In today's episode, we welcome Dr. Conor Steuer, which is Associate Professor at the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, USA, to discuss adaptation of thyroid cancer guidelines to local care settings. We touch on strategies for guideline implementation and how to overcome potential barriers. Target Audience: Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners. Learning Objective(s): After completing this educational activity, learners will be able to: • Re ..read more

In today’s episode, we welcome Dr. Antonio Matrone, an endocrinologist at the University of Pisa, to discuss the many factors involved in treatment decision-making and strategies for the management of patients with advanced thyroid cancer where an oncogenic driver has been identified. References Matrone A et al. Differentiated thyroid cancer, from active surveillance to advanced therapy: Toward a personalized medicine. Front Endocrinol (Lausanne) 2019;10:884 Sherman SI. Evolution of targeted therapies for thyroid carcinoma. Trans Am Clin Climatol Assoc 2019;130:255–265 Filetti S et al. ESMO C ..read more

In today’s episode, we welcome expert Oncologist Dr. Lori Wirth and expert Pathologist Dr. Thomas Giordano to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches. References Kilagat K, Griffin MJ, Baik F, et al. Thyroid Care Collaborative: an electronic health record facilitating multidisciplinary management of thyroid cancer. Int J Endo Oncol 2018;5(1):IJE03 Target Audience: Oncologists, pathologists and ot ..read more

Developments in RET-targeted therapies have led to a paradigm shift in the management of advanced thyroid cancer. However, resistance to these drugs has been observed to develop through a variety of mechanisms, so precise monitoring is required to detect and react to disease development. This episode offers insight into relevant mechanisms of resistance to RET inhibitors in thyroid cancer. It also considers how strategies such as combinations of targeted therapies and liquid biopsy could potentially help tackle the development of resistance. To answer questions on this topic, we have invited P ..read more

Rearranged during transfection (RET) and tropomyosin receptor kinase (TRK) fusions are involved in various adult and paediatric cancers, including thyroid cancers. There is a high mortality rate for some of these cancers, partly due to the lack of efficient detection, diagnosis, and prognosis. The US and European guidelines recommend genomic testing as a part of standard diagnostic evaluations for some cancers to identify driver mutations for which effective therapies or clinical trials are available. However, adherence to genomic testing guidelines presents challenges to practitioners, includ ..read more

Adult guidelines for acute myeloid leukaemia recommend determining a patient’s fitness before treating with standard therapy, but what does this mean, what are the implications, and how does this work in practice for both adults and children? To answer our questions on this topic, we’ve invited the expertise of Dr Courtney DiNardo, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. References Heuser et al. Ann Oncol. 2020 Mar 17;S0923-7534(20)36079-8 PDQ Adult Treatment Editorial Board. Adult Acute Myeloid Leukemia Treatment (PDQ®): Health ..read more

Despite available treatments, many patients with acute myeloid leukaemia, or AML, are in need of additional therapeutic options. Thankfully, there hundreds of clinical trials for new interventions that could rectify this, but which options can we start to consider, for which patients and when? To answer our questions on this topic, we’ve invited the expertise of Dr Navel Daver, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. References: Swords, et al. Blood. 2018;131(13):1415-1424 Stahl, et al. Curr Oncol Rep. 2019;21(4 ..read more

For patients with myelodysplastic syndrome, or MDS, their therapy options vary considerably depending on their prognosis and risk of developing AML. Today we discuss risk stratification systems and their rationale, and consider their utility in clinical practice. To answer our questions on this topic, we welcome Professor Detlaf Haase, medical director of the special diagnostic laboratories at the clinic for hematology & medical oncology in at the University Medical Center in Göttingen, Germany. References Greenberg, et al. Blood. 2012 Sep 20; 120(12): 2454–2465 Montalban-Bravo & Garc ..read more

A ..read more